GIP
Glucose-Dependent Insulinotropic Polypeptide (GIP)
An incretin hormone that stimulates insulin secretion in a glucose-dependent manner. The GIP receptor is the second target of tirzepatide, contributing to its superior weight loss.
Mechanism of Action
GIP binds to GIPR receptors on pancreatic beta cells (stimulating insulin), adipocytes (promoting fat storage or mobilization depending on context), and bone cells (promoting bone formation).
Health Claims & Evidence
Stimulates insulin secretion in a glucose-dependent manner
Supports bone formation
Contributes to weight loss when combined with GLP-1
Short-Term Effects
Insulin secretion, bone formation support.
Long-Term Effects
Research use primarily as standalone.
Side Effects
Potential fat storage effects at high doses.
Contraindications
Research use only as standalone.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
GIP and incretin pharmacology
Drucker et al. · Cell Metabolism · 2006
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on GIP and related peptides, and prepare an educational research summary.
Explore Research